nach oben

Notfall + Rettungsmedizin

Erschienen in:

01.10.2006 | Leitthema

Infarktbedingter kardiogener Schock

Diagnose, Monitoring und Therapie

verfasst von: PD Dr. M. Buerke, M. Ruß, K. Werdan

Erschienen in: Notfall + Rettungsmedizin | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der kardiogene Schock ist die häufigste Todesursache beim akuten Myokardinfarkt. Die Sterblichkeit liegt bei 50–80%. Der kardiogene Schock ist durch eine kritische Verminderung der kardialen Pumpleistung mit Hypoperfusion und inadäquater Sauerstoffversorgung der peripheren Organe gekennzeichnet. Die Diagnose „infarktbedingter kardiogener Schock“ wird anhand klinischer und hämodynamischer Kriterien gestellt. Rasche diagnostische und therapeutische Maßnahmen können die Todesspirale des kardiogenen Schocks positiv beeinflussen. Wichtig sind in diesem Zusammenhang die schnelle Reperfusion der Infarktarterie und eine effektive hämodynamische Stabilisierung durch die medikamentöse Therapie.

Vorheriger Artikel Traumatischer Schock

Nächster Artikel Anaphylaxie und anaphylaktischer Schock

Anderson RD, Ohman EM, Holmes DR Jr et al. (1997) Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. J Am College Cardiol 30: 708–715CrossRef

Buerke M, Murohara T, Skurk C et al. (1995) Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 92: 8031–8035CrossRefPubMed

Buerke M, Schwertz H, Seitz W et al. (2001) Novel small molecule Inhibitor of C1 s exerts cardioprotective effects in ischemia-reperfusion Injury in rabbits. J Immunol 167: 5375–5380PubMed

Chanques G, Jaber S, Barbotte E et al. (2006) Impact of systematic evaluation of pain and agitation in an intensive care unit. Crit Care Med 34: 1691–1699CrossRefPubMed

Chen EW, Canto JG, Parsons LS et al. (2003) Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation 108: 951–957CrossRefPubMed

Cotter G, Kaluski E, Milo O et al. (2003) LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 24: 1287–1295CrossRefPubMed

Cotter G, Williams SG, Vered Z, Tan LB (2003b) Role of cardiac power in heart failure. Curr Opin Cardiol 18: 215–222CrossRefPubMed

Cuffe MS, Califf RM, Adams KF et al. (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287: 1541–1547CrossRefPubMed

Delle Karth G, Buberl A, Geppert A et al. (2003) Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 47: 1251–1256CrossRefPubMed

10.

Durrer JD, Lie KI, van Capelle FJ, Durrer D (1982) Effect of sodium nitroprusside on mortality in acute myocardial infarction. N Engl J Med 306: 1121–1128PubMed

11.

Field S, Kelly SM, Macklem PT (1982) The oxygen cost of breathing in patients with cardiorespiratory disease. Am Rev Respir Dis 126: 9–13PubMed

12.

Fincke R, Hochman JS, Lowe AM et al. (2004) Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am College Cardiol 44: 340–348CrossRef

13.

Friedrich JO, Adhikari N, Herridge MS, Beyene J (2005) Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 142: 510–524PubMed

14.

Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ et al. (in press) Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Failure (corrected proof)

15.

Granger CB, Mahaffey KW, Weaver WD et al. (2003) Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108: 1184–1190CrossRefPubMed

16.

Heer T, Zeymer U, Juenger C et al. (2006) Beneficial effects of abciximab in patients with primary percutaneous intervention for acute st segment elevation myocardial infarction in clinical practice. Heart, hrt.2005.085456

17.

Hochman JS, Boland J, Sleeper LA et al. (1995) Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an international registry. Circulation 91: 873–881PubMed

18.

Hochman JS, Sleeper LA, Webb JG et al. (2006) Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 295: 2511–2515CrossRefPubMed

19.

Hochman JS, Sleeper LA, Webb JG et al. (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341: 625–634CrossRefPubMed

20.

Hochman JS, Sleeper LA, White HD et al. (2001) One-year survival following early revascularization for cardiogenic shock. JAMA 285: 190–192CrossRefPubMed

21.

Jolly S, Newton G, Horlick E et al. (2005) Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 96: 1617–1620CrossRefPubMed

22.

Metra M, Nodari S, Aloia A et al. (2002) Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am College Cardiol 40: 1248–1258CrossRef

23.

Ohman EM, Nanas J, Stomel RJ et al. (2005) Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis 19: 33–39CrossRefPubMed

24.

Rudiger A, Gasser S, Fischler M et al. (2006) Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med (in press)

25.

Ruß M, Prondzinsky R, Reith S et al. (2005) Profound hemodynamic improvement following levosimendan in patients with acute myocardial infarction and severe cardiogenic shock. Circulation Suppl 112: 11–423CrossRef

26.

Sanborn TA, Sleeper LA, Webb JG et al. (2003) Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol 42: 1373–1379CrossRefPubMed

27.

Slater J, Brown RJ, Antonelli TA et al. (2000) Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 36: 1117–1122CrossRefPubMed

28.

White HD, Assmann SF, Sanborn TA et al. (2005) Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Trial. Circulation 112: 1992–2001CrossRefPubMed

29.

Zion MM, Balkin J, Rosenmann D et al. (1990) Use of pulmonary artery catheters in patients with acute myocardial infarction. Analysis of experience in 5,841 patients in the SPRINT Registry. SPRINT Study Group. Chest 98: 1331–1335PubMed

Titel: Infarktbedingter kardiogener Schock
Diagnose, Monitoring und Therapie
verfasst von: PD Dr. M. Buerke
M. Ruß
K. Werdan
Publikationsdatum: 01.10.2006
Verlag: Springer-Verlag
Erschienen in: Notfall + Rettungsmedizin / Ausgabe 6/2006
Print ISSN: 1434-6222
Elektronische ISSN: 1436-0578
DOI: https://doi.org/10.1007/s10049-006-0854-7

Springerpflege

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2006

Perspektiven in der Schockforschung

Schock 2006 - eine Netzwerkanalyse

Abstracts: DIVI-Kongress, Notfallmedizinische Themen

Alte Medikamente und neue Zulassungsverfahren: Akrinor bleibt verkehrsfähig und ein Nachzulassungsantrag für Arginin Vasopressin ist gestellt

Traumatischer Schock

Schwere Sepsis und septischer Schock